Orchid Pharma Limited (ORCHPHARMA NSE) stock market data APIs
INR745.7744
-24.26(-3.3%)
as of July 15, 2025
Try our APIs with
free plan!
Orchid Pharma Limited Financial Data Overview
Price chart is built with
Anychart
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is based in Narsinghpur, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
Prev. Close
745.7744
Open
721.5172
High
753.8984
Low
721.5172
52 wk Range
603.8-1997.4
Market Cap
38 242 M
P/E Ratio
37.4313
Shares Outstanding
50 719 K
Revenue
9 219 M
EPS
4.4
Beta
1.795
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Orchid Pharma Limited data using free add-ons & libraries
Get Orchid Pharma Limited Fundamental Data
Orchid Pharma Limited Fundamental data includes:
- Net Revenue: 9 219 M
- EBITDA: 1 172 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-26
- EPS/Forecast: 4.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Orchid Pharma Limited News
New
Orchid Projects Loss for Q2: Is RMBS Strategy Backfiring?
Orchid Island Capital, Inc. ORC has released its estimated results for the second quarter of 2025. The company estimates a net loss of 29 cents per share for the quarter ending June 30, 2025. This in...
Orchid Offers 20.1% Dividend Yield: A Powerful Income Play?
One of the most closely watched aspects of Orchid Island Capital ORC is its financial profile, particularly its dividend policy. This specialty finance mREIT company, which invests in residential mor...
Is Orchid Stock Worth Buying for Its Lucrative 20.3% Dividend Yield?
Orchid Island Capital, Inc. ORC has a record of paying out regular dividends, currently yielding a staggering 20.3% compared with the industry average of 12.4%. The company has increased its dividend ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
